Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
VectivBio AG · Short Bowel Syndrome
Phase 3
Active, not recruiting
158
2025-07
Evidence dashboardStudies since 2018Updated Jul 31, 2026
ApraglutideClinical Trials.
A source-linked view of every Apraglutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 11
- Recruiting
- 0
- Completed
- 8
- Terminated
- 1
- Results posted
- 4
- Average enrollment
- 44
- Countries
- 21
- Highest phase
- Phase 3
Largest indexed study
164 participants · NCT04627025 →Developer / research origin
Ironwood Pharmaceuticals
Evidence summary
Activity is not efficacy.
Apraglutide appears in 11 indexed studies: 0 recruiting, 8 completed and 4 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Apraglutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
NCT IDStudyPhase / statusEnrollmentUpdated
A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function
VectivBio AG · Hepatic Impairment
Phase 1
Completed
16
2025-07
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
VectivBio AG · Short Bowel Syndrome
Phase 2
Completed
10
2025-06
Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF
VectivBio AG · Short Bowel Syndrome
Phase 3
Completed
164
2024-11
Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support
GlyPharma Therapeutics · Short Bowel Syndrome
Phase 1 / Phase 2
Completed
8
2024-10
Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
VectivBio AG · Chronic Kidney Disease
Phase 1
Completed
16
2024-10
Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation
VectivBio AG · Healthy Subjects
Phase 1
Completed
34
2024-10
Showing 6 of 8 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Phase 2
Terminated
31
2025-10
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
GlyPharma Therapeutics · Lymphoma, Non-Hodgkin's, Adult · Lymphoma, Hodgkin's, Adult
Phase 1 / Phase 2
Withdrawn
0
2024-10
Full study index
Search Apraglutide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
11 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 41903849 ↗Ekhlas D, Verbiest A, Stas M, De Meyere L, Vandermeulen G, Toth J, Geboers K, Timmermans L, Verspecht C, Wauters L, Vermeersch P, Jeppesen PB, Verbeke K, Joly F, Derrien M, Raes J, Vanuytsel T. Early ecological changes in intestinal microbiota with the long-acting GLP-2 analog apraglutide in short bowel syndrome. Clin Nutr ESPEN. 2026 Jun;73:103138. doi: 10.1016/j.clnesp.2026.103138. Epub 2026 Mar 26.Linked from NCT04964986PMID 39461299 ↗Verbiest A, Hvistendahl MK, Bolognani F, Li C, Youssef NN, Huh S, Menys A, Bhatnagar G, Vanslembrouck R, Peeters R, Sartoris R, Vermeersch P, Wauters L, Verbeke K, Jeppesen PB, Joly F, Vanuytsel T. Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon-in-continuity: A multicenter, open-label, metabolic balance study. Clin Nutr. 2024 Dec;43(12):158-166. doi: 10.1016/j.clnu.2024.10.011. Epub 2024 Oct 16.Linked from NCT04964986PMID 34287970 ↗Eliasson J, Hvistendahl MK, Freund N, Bolognani F, Meyer C, Jeppesen PB. Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial. JPEN J Parenter Enteral Nutr. 2022 May;46(4):896-904. doi: 10.1002/jpen.2223. Epub 2021 Sep 7.Linked from NCT03415594PMID 38465515 ↗Greig G, Youssef NN, Bolognani F. Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long-Acting, Synthetic glucagon-like peptide-2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function. J Clin Pharmacol. 2024 Jun;64(6):744-754. doi: 10.1002/jcph.2423. Epub 2024 Mar 11.Linked from NCT04699032
Related pages
Keep researching Apraglutide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.